Morrison Aimee, Myers Kasiani, Streich-Tilles Tara
Division of Pediatric and Adolescent Gynecology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.
Division of Hematopoietic Stem Cell Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.
J Cancer Surviv. 2024 Nov 18. doi: 10.1007/s11764-024-01709-w.
To characterize the rate of human papillomavirus (HPV) vaccine uptake among adolescents after hematopoietic stem cell transplant (HSCT).
This retrospective study evaluated the vaccine history of adolescent patients ≥ 11 years of age who underwent either auto- or allo-HSCT between 2015 and 2022 at a tertiary care medical center. Logistic regression was used to examine bivariate associations between HPV vaccine uptake and covariates including demographic factors, indication for and type of HSCT, receipt of HPV vaccine prior to transplant, and receipt of other vaccines after transplant.
Among 119 (n = 53 female; n = 66 male) eligible patients, 66 (55.5%) received at least one dose of the HPV vaccine after HSCT. Among those who initiated vaccination, 45/66 (68.2%) completed two or more doses. Of the 69 patients who were eligible to receive the vaccine prior to HSCT, 19/36 (52%) were vaccinated both before and after HSCT, compared to 14/33 (42%) who did not receive the vaccine before HSCT but chose to be vaccinated after HSCT. No statistically significant difference was identified between those who did and did not initiate HPV vaccination after HSCT among covariates examined.
Rate of HPV vaccine uptake after HSCT was lower than the rate of other recommended vaccines. Receiving HPV vaccine prior to HSCT was not associated with HPV re-uptake after HSCT.
HPV vaccination continues to be suboptimal in HSCT survivorship and should be a targeted goal for improvement in preventing secondary malignancy in this high-risk population.
描述造血干细胞移植（HSCT）后青少年人乳头瘤病毒（HPV）疫苗的接种率。
这项回顾性研究评估了2015年至2022年间在一家三级医疗中心接受自体或异体HSCT的11岁及以上青少年患者的疫苗接种史。采用逻辑回归分析HPV疫苗接种与协变量之间的双变量关联，协变量包括人口统计学因素、HSCT的指征和类型、移植前HPV疫苗接种情况以及移植后其他疫苗接种情况。
在119名（n = 53名女性；n = 66名男性）符合条件的患者中，66名（55.5%）在HSCT后接种了至少一剂HPV疫苗。在开始接种疫苗的患者中，45/66（68.2%）完成了两剂或更多剂的接种。在69名HSCT前有资格接种疫苗的患者中，19/36（52%）在HSCT前后均接种了疫苗，而14/33（42%）在HSCT前未接种疫苗但在HSCT后选择接种。在所检查的协变量中，HSCT后开始和未开始接种HPV疫苗的患者之间未发现统计学上的显著差异。
HSCT后HPV疫苗的接种率低于其他推荐疫苗的接种率。HSCT前接种HPV疫苗与HSCT后再次接种HPV疫苗无关。
HPV疫苗接种在HSCT幸存者中仍然不理想，应成为改善这一高危人群继发性恶性肿瘤预防的目标。
